The rates of malignancy in patients with psoriasis do not appear to be increased in those receiving etanercept. In placebo-controlled, randomized studies, 8 of 933 etanercept treated patients were diagnosed with malignancy whereas 1 in 414 patients receiving placebo were diagnosed with malignancy. The rate of lymphoma was threefold greater in patients receiving etaner-cept than in the general population. A cohort study by Gelfand though found that both rheumatoid arthritis and psoriasis patients are at a threefold increased risk of developing lymphoma. Taking this into account, analysis of the effects of etanercept or any other immunosuppressive therapy must consider the inherited risk of lymphoma to that specific disease population.
Was this article helpful?
Thank you for deciding to learn more about the disorder, Osteoarthritis. Inside these pages, you will learn what it is, who is most at risk for developing it, what causes it, and some treatment plans to help those that do have it feel better. While there is no definitive “cure” for Osteoarthritis, there are ways in which individuals can improve their quality of life and change the discomfort level to one that can be tolerated on a daily basis.